VitroGel® Hydrogel Matrix enables the controlled delivery of bioactive Qu-SeNPs, accelerating bone defect healing and enhancing therapeutic potential for regenerative medicine. Hydrogel: VitroGel® Hydrogel Matrix (Cat. No: VHM01) The development of biomimetic hydrogels has significantly advanced the field of regenerative medicine by providing an extracellular matrix-like environment that supports cell survival and function. In bone […]
Abstract: The invasive nature of cancer, driven by epithelial-to-mesenchymal transition (EMT), is a critical process influenced by external cues from the tumor microenvironment, such as extracellular matrix (ECM) composition. The ECM primes cells for EMT and metastasis, making it a key topic in understanding disease progression. For example, in glioblastoma multiforme (GBM), a grade IV […]
VitroGel® supports 3D spheroid models for evaluating basroparib’s efficacy in overcoming MEK inhibitor resistance in KRAS-mutated colorectal cancer. Hydrogel: VitroGel® RGD (Cat. No: TWG003) The study on basroparib’s role in overcoming MEK inhibitor resistance in KRAS-mutated colorectal cancer (CRC) highlights the importance of innovative in vitro models that accurately recapitulate tumor microenvironments. Using VitroGel®, a […]
VitroINK® provided a xeno-free, structurally supportive bioink that enabled the precise 3D bioprinting of a functional testis model, facilitating cell viability, maturation, and in vitro spermatogenesis research. Fertility preservation following pediatric cancer therapy has become a critical area of research, as over 80% of childhood cancer survivors reach adulthood, yet up to 66% of male […]
VitroGel® 3D provided a scaffold-free yet supportive matrix that stabilized adipose organoids for imaging and analysis, enhancing the reliability of in vitro obesity research. Hydrogel:VitroGel® 3D (Cat. No: TWG001) Obesity and metabolic diseases remain urgent global health challenges, yet studying human adipose tissue in vitro is complicated by the limitations of 2D cultures and scaffold-based […]
Biomarker Cyto3D® Live-Dead Assay Kit (Cat. No: BM01) The study explores the application of tumor organoid technology in borderline ovarian tumors (BOT), a category of tumors with limited treatment options and resistance to conventional chemotherapy. Researchers established patient-derived organoids (PDOs) to model BOT and evaluate potential therapeutic compounds, particularly Bractoppin, a BRCA1 carboxy-terminal domain (BRCT) […]
Culture apical-out organoids with xeno-free VitroGel® system
Hydrogel: VitroGel® ORGANOID 3 (Cat. No: VHM04-3) Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with limited treatment options and poor patient survival rates. A major challenge in treating PDAC is the tumor’s ability to create a protective barrier of mucins, which shields cancer cells from immune attacks and reduces the effectiveness of […]
BiomarkerCyto3D® Live-Dead Assay Kit (Cat. No: BM01) Cancer research has long been challenged by the complexity of tumor-immune interactions. Traditional 2D cell cultures and animal models often fail to capture the intricate tumor microenvironment (TME), limiting their relevance to human biology. Patient-derived precision-cut tumor slices (PCTS) offer a promising solution by preserving the tumor’s architecture […]
VitroGel® Hydrogel for In Vivo / Tissue Engineering Revolutionizing Cartilage Repair: Combining the VitroGel® System with a Bendable-Tip Arthroscopic Device for Controlled Hydrogel Extrusion
